Matches in SemOpenAlex for { <https://semopenalex.org/work/W2066752590> ?p ?o ?g. }
- W2066752590 abstract "Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DCBackground. Achievement of CR is generally associated with improved clinical outcomes for patients (pts) with MM and represents a primary endpoint of current clinical trials. The GIMEMA Italian Myeloma Network phase 3 study demonstrated that VTD regimen was superior over thalidomide-dexamethasone (TD) as induction therapy prior to and as consolidation therapy after the double ASCT for newly diagnosed MM (rate of >nCR: 31% vs 11% (p nCR affected by VTD resulted in extended progression-free survival (PFS), prediction of CR by pharmacogenomic tools is likely to be an important goal to prospectively select those pts who are more likely to benefit from a given therapy.Methods. We assessed the ability of GEP to predict attainment of CR in 122 pts enrolled in the VTD arm of the study. CD138+ plasma cells were obtained at diagnosis from each pts and were profiled for their gene expression (Affymetrix U133 Plus2.0 platform).Results. 34/122 pts (28%) who were included in the present analysis achieved a ≥nCR after VTD induction therapy and were characterized by the differential expression of 2157 probesets (p≤0.01). According to the unsupervised hierarchical clustering, the population of 122 profilated pts resulted stratified into 2 subgroups, the first one including 79% and the second one 21% of ≥nCR pts.To obtain a classifier for response to VTD induction therapy, the differentially expressed genes was analyzed to identify a small group of predictor genes. The best predictive capability was obtained with a 41-gene classifier that provided 88% sensitivity, 97% specificity, 91% PPV and 95% NPV. A GeneGo® network analysis showed that the most relevant network nodes included tumour suppressor genes, genes involved in inflammatory response and genes involved in B cell development.To asses the relevance to know since diagnosis the sensitivity for a particular therapy, we evaluated the prognostic impact of the response prediction in our clinical context. Pts predicted to be responder to VTD induction therapy according to the 41-gene classifier were more likely to attain a ≥nCR after the consolidation therapy. The 3 years estimate of PFS of pts ≥nCR after the consolidation therapy was significantly higher as compared to pts who failed this objective (p=0.03).Conclusions. GEP analysis of a subgroup of pts who received VTD induction therapy provided a 41-gene classifier that was able to predict attainment of >nCR and, conversely, failure to achieve at least nCR in 91% and 95% of cases, respectively. These favorable results might represent a first step towards the possible application of a tailored therapy based on the single patient's genetic background.Supported by: Fondazione Del Monte di Bologna e Ravenna, Ateneo RFO grants (M.C.) BolognAIL.Citation Format: Carolina Terragna, Daniel Remondini, Marina Martello, Annalisa Pezzi, Francesca Patriarca, Anna Levi, Lucia Pantani, Daniela Donnarumma, Lorenzo Montanaro, Claudia Crippa, Sarah Bringhen, Alessandro Rambaldi, Massimo Offidani, Paolo Corradini, Franco Narni, Giuseppe Fioritoni, Alfonso Zaccaria, Luca Baldini, Tommaso Caravita, Giorgio La Nasa, Sergio Cortellazzo, Giovanni Martinelli, Michele Cavo. A 41-gene signature predicts complete response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) as induction therapy prior to autologous stem-cell transplantation (ASCT) in multiple myeloma (MM). [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2207. doi:10.1158/1538-7445.AM2013-2207" @default.
- W2066752590 created "2016-06-24" @default.
- W2066752590 creator A5002485247 @default.
- W2066752590 creator A5002668632 @default.
- W2066752590 creator A5024851188 @default.
- W2066752590 creator A5025807854 @default.
- W2066752590 creator A5034587847 @default.
- W2066752590 creator A5036642940 @default.
- W2066752590 creator A5040474758 @default.
- W2066752590 creator A5043718907 @default.
- W2066752590 creator A5047717543 @default.
- W2066752590 creator A5053560614 @default.
- W2066752590 creator A5055401685 @default.
- W2066752590 creator A5057333997 @default.
- W2066752590 creator A5057705097 @default.
- W2066752590 creator A5065076609 @default.
- W2066752590 creator A5071128692 @default.
- W2066752590 creator A5071926851 @default.
- W2066752590 creator A5073761054 @default.
- W2066752590 creator A5073975207 @default.
- W2066752590 creator A5074464839 @default.
- W2066752590 creator A5077270786 @default.
- W2066752590 creator A5079770116 @default.
- W2066752590 creator A5080985835 @default.
- W2066752590 creator A5083644983 @default.
- W2066752590 date "2013-04-15" @default.
- W2066752590 modified "2023-09-25" @default.
- W2066752590 title "Abstract 2207: A 41-gene signature predicts complete response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) as induction therapy prior to autologous stem-cell transplantation (ASCT) in multiple myeloma (MM)." @default.
- W2066752590 doi "https://doi.org/10.1158/1538-7445.am2013-2207" @default.
- W2066752590 hasPublicationYear "2013" @default.
- W2066752590 type Work @default.
- W2066752590 sameAs 2066752590 @default.
- W2066752590 citedByCount "0" @default.
- W2066752590 crossrefType "proceedings-article" @default.
- W2066752590 hasAuthorship W2066752590A5002485247 @default.
- W2066752590 hasAuthorship W2066752590A5002668632 @default.
- W2066752590 hasAuthorship W2066752590A5024851188 @default.
- W2066752590 hasAuthorship W2066752590A5025807854 @default.
- W2066752590 hasAuthorship W2066752590A5034587847 @default.
- W2066752590 hasAuthorship W2066752590A5036642940 @default.
- W2066752590 hasAuthorship W2066752590A5040474758 @default.
- W2066752590 hasAuthorship W2066752590A5043718907 @default.
- W2066752590 hasAuthorship W2066752590A5047717543 @default.
- W2066752590 hasAuthorship W2066752590A5053560614 @default.
- W2066752590 hasAuthorship W2066752590A5055401685 @default.
- W2066752590 hasAuthorship W2066752590A5057333997 @default.
- W2066752590 hasAuthorship W2066752590A5057705097 @default.
- W2066752590 hasAuthorship W2066752590A5065076609 @default.
- W2066752590 hasAuthorship W2066752590A5071128692 @default.
- W2066752590 hasAuthorship W2066752590A5071926851 @default.
- W2066752590 hasAuthorship W2066752590A5073761054 @default.
- W2066752590 hasAuthorship W2066752590A5073975207 @default.
- W2066752590 hasAuthorship W2066752590A5074464839 @default.
- W2066752590 hasAuthorship W2066752590A5077270786 @default.
- W2066752590 hasAuthorship W2066752590A5079770116 @default.
- W2066752590 hasAuthorship W2066752590A5080985835 @default.
- W2066752590 hasAuthorship W2066752590A5083644983 @default.
- W2066752590 hasConcept C126322002 @default.
- W2066752590 hasConcept C143998085 @default.
- W2066752590 hasConcept C203092338 @default.
- W2066752590 hasConcept C2776364478 @default.
- W2066752590 hasConcept C2777478702 @default.
- W2066752590 hasConcept C2779050716 @default.
- W2066752590 hasConcept C2779609412 @default.
- W2066752590 hasConcept C2780401358 @default.
- W2066752590 hasConcept C2781413609 @default.
- W2066752590 hasConcept C2908647359 @default.
- W2066752590 hasConcept C2911091166 @default.
- W2066752590 hasConcept C535046627 @default.
- W2066752590 hasConcept C71924100 @default.
- W2066752590 hasConcept C99454951 @default.
- W2066752590 hasConceptScore W2066752590C126322002 @default.
- W2066752590 hasConceptScore W2066752590C143998085 @default.
- W2066752590 hasConceptScore W2066752590C203092338 @default.
- W2066752590 hasConceptScore W2066752590C2776364478 @default.
- W2066752590 hasConceptScore W2066752590C2777478702 @default.
- W2066752590 hasConceptScore W2066752590C2779050716 @default.
- W2066752590 hasConceptScore W2066752590C2779609412 @default.
- W2066752590 hasConceptScore W2066752590C2780401358 @default.
- W2066752590 hasConceptScore W2066752590C2781413609 @default.
- W2066752590 hasConceptScore W2066752590C2908647359 @default.
- W2066752590 hasConceptScore W2066752590C2911091166 @default.
- W2066752590 hasConceptScore W2066752590C535046627 @default.
- W2066752590 hasConceptScore W2066752590C71924100 @default.
- W2066752590 hasConceptScore W2066752590C99454951 @default.
- W2066752590 hasLocation W20667525901 @default.
- W2066752590 hasOpenAccess W2066752590 @default.
- W2066752590 hasPrimaryLocation W20667525901 @default.
- W2066752590 hasRelatedWork W2232626202 @default.
- W2066752590 hasRelatedWork W2522666922 @default.
- W2066752590 hasRelatedWork W2529767592 @default.
- W2066752590 hasRelatedWork W2539381491 @default.
- W2066752590 hasRelatedWork W2552062425 @default.
- W2066752590 hasRelatedWork W2555678589 @default.
- W2066752590 hasRelatedWork W2556245410 @default.
- W2066752590 hasRelatedWork W2560547360 @default.
- W2066752590 hasRelatedWork W2564479592 @default.
- W2066752590 hasRelatedWork W2574051972 @default.
- W2066752590 hasRelatedWork W2576564387 @default.
- W2066752590 hasRelatedWork W2580684155 @default.